Cleveland HeartLab, an affiliate of the Cleveland Clinic, has developed a profile of tests focused on managing and reducing inflammation, a root cause of heart disease. Using an enzyme immunoassay (a biochemical technique used to detect the presence of an antibody in a sample), CHL uses its CardioMPO technology to test for myeloperoxidase in human plasma. The product received its FDA approval in May of 2005 for use on the market. Cleveland HeartLab purchased that technology in Nov. 2009 from Cleveland-based PrognostiX. The company bills itself as a specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. But the company doesn't stop there. CHL also runs a research and development laboratory where next-generation cardiovascular disease biomarkers are being developed for use in the clinical community.